Butterfly Network, Kardium, OmniAb, Quanterix Stocks Rise on FDA Clearances, Partnerships

Biotech stocks Butterfly Network (BFLY) and Kardium (KARD) saw significant gains on June 19, 2026, following FDA 510(k) clearances for their respective medical devices. OmniAb (OM) and Quanterix (QTRX) also advanced after announcing new partnership agreements. Butterfly Network (BFLY) shares climbed 18.2% to $1.29 after receiving FDA clearance for its Butterfly iQ+ point-of-care ultrasound system. Kardium (KARD) stock rose 11.5% to $1.36 following FDA clearance for its Globe Mapping and Ablation System, designed for atrial fibrillation treatment. OmniAb (OM) shares increased 9.2% to $4.01 after announcing an antibody discovery partnership with a global biopharmaceutical company. Quanterix (QTRX) gained 8.5% to $1.65, driven by a collaboration with the Alzheimer's Clinical Trials Consortium to measure biomarkers in a clinical trial.